Core Points - The National Healthcare Security Administration (NHSA) has published the preliminary results of the review for the 2025 National Basic Medical Insurance (BMI) and commercial insurance innovative drug directories, with 534 drug names approved for the BMI directory and 121 for the commercial insurance directory [1][2] - The review process includes initial review, public announcement of results, re-evaluation, and final announcement, with the initial review being the first step in the overall directory adjustment process [1][2] Summary by Sections Initial Review Results - A total of 718 submissions were received for the BMI directory, involving 633 drug names, with 534 passing the initial review [2] - The number of drugs passing the initial review from outside the directory increased significantly from 249 in 2024 to 310 in 2025 [2] - The approved drugs cover various fields, including oncology, chronic diseases, and rare diseases, with notable CAR-T products and antibody-drug conjugates (ADCs) included [2][3] Pricing and Evaluation - Some high-priced drugs, such as CAR-T therapies and enzyme replacement therapies, have passed the initial review but may not meet the BMI's implicit pricing thresholds [3] - The NHSA emphasizes that passing the initial review does not guarantee inclusion in the BMI directory, as further evaluations and negotiations are required [3][4] Payment Mechanisms and Sustainability - The need for differentiated payment mechanisms to support innovative drugs while ensuring sustainable development is highlighted [4][5] - The introduction of the commercial insurance innovative drug directory aims to enhance service attributes and drive transformation in the commercial insurance sector [5][6] Dual Directory System - The commercial insurance directory received 141 submissions, with 121 drug names passing the initial review, indicating a strong focus on innovative and high-value drugs [5][6] - The dual directory system is expected to foster innovation in drug development and improve patient access to treatments [7]